CD4+ T cells expressing IL-10 and chimeric antigen receptors and uses thereof
AssigneeTr1x, Inc.
InventorsJan Egbert De Vries, Maria Grazia Roncarolo, Xavier Paliard, David De Vries
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a population of CD4IL-10/CAR cells (autologous or allogeneic single-donor and allogeneic polydonor) generated by genetically modifying CD4+ T cells to express IL-10 and a chimeric antigen receptor. Further provided are methods of generating the CD4IL-10/CAR cells and methods of using the CD4IL-10/CAR cells for immune tolerization, treating GvHD, cell and organ transplantation, cancer, and other autoimmune and inflammatory disorders.
Claims5
A population of genetically modified CD4+ cells (CD4IL-10/CAR cells), wherein the CD4IL-10/CAR cells in the population comprise:
- (a) a first exogenous polynucleotide segment encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain targeting an autoantigen or antigen associated with an inflammatory or autoimmune disease;
- and
- (b) a second exogenous polynucleotide segment encoding interleukin-10 (IL-10),
- wherein the CD4IL-10/CAR cells express the CAR and secrete IL-10, and
- wherein the population of CD4IL-10/CAR cells reduce hyperactivity of NLRP3 inflammasome or inhibit the production of a pro-inflammatory cytokine when administered in a therapeutically sufficient amount to a patient who has an inflammatory or autoimmune disease.
Dependencies are inferred from the claim text.